Psoriatic Arthritis Treatment Market: Innovation-Driven Growth on the Rise

Psoriatic Arthritis Treatment Market Size, Share & Forecast 2025–2034

The global psoriatic arthritis treatment market is projected to grow from USD 12.18 billion in 2024 to approximately USD 25.89 billion by 2034, registering a compound annual growth rate (CAGR) of 7.83% during the forecast period from 2025 to 2034.

Market Overview

The market is highly fragmented, with the presence of both established pharmaceutical giants and emerging biopharma companies. Key players operating in this space include AbbVie Inc., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson), Novartis AG, Amgen Inc., Biogen Inc., Pfizer Inc., Eli Lilly and Company, UCB S.A., Bristol-Myers Squibb Company, and Merck & Co., Inc. These companies are actively involved in research, development, and commercialization of innovative biologics, small molecules, and targeted immunotherapies aimed at treating PsA more effectively.

Psoriatic Arthritis Treatment Market Key Takeaways

• The global psoriatic arthritis treatment market was valued at USD 12.18 billion in 2024.
• It is projected to reach USD 25.89 billion by 2034.
• The psoriatic arthritis treatment market is expected to grow at a CAGR of 7.83% from 2025 to 2034.

Psoriatic Arthritis Treatment Market Growth Factors

• Rising research and development investment and activities can boost the psoriatic arthritis treatment market.
• Growing awareness and diagnosis of psoriatic arthritis can boost the psoriatic arthritis treatment market.

Role of Artificial Intelligence in Psoriatic Arthritis Treatment Market

Artificial Intelligence (AI) is playing an increasingly transformative role in the psoriatic arthritis treatment market, enhancing various aspects of disease management, from early detection to personalized therapy. Key contributions include:

1. Early Diagnosis and Predictive Analytics
   AI-powered tools can analyze medical imaging, electronic health records, and genetic data to detect psoriatic arthritis at earlier stages. Machine learning algorithms help in identifying patterns and risk factors that may not be easily visible to clinicians, enabling earlier intervention and improved patient outcomes.

2. Personalized Treatment Plans
   AI models assist in tailoring treatment strategies based on individual patient profiles, considering factors like disease severity, comorbidities, and response to previous therapies. This leads to more effective and targeted treatment regimens, reducing trial-and-error approaches.

3. Drug Discovery and Development
   AI accelerates drug discovery by analyzing large datasets to identify potential drug candidates, predict their effectiveness, and optimize clinical trial designs. This reduces the time and cost associated with bringing new psoriatic arthritis therapies to market.

4. Remote Monitoring and Patient Engagement
   AI-integrated digital health platforms and wearable medical devices enable continuous monitoring of symptoms and treatment adherence. These tools provide real-time data to healthcare providers, facilitating proactive care and adjustments to therapy as needed.

Driving Factors

1. Increasing Research and Development Investments
   The market is witnessing significant growth due to rising investments in research and development by pharmaceutical and biotechnology companies. These efforts are leading to the development of advanced biologics, targeted therapies, and personalized treatment options, thereby expanding the therapeutic landscape for psoriatic arthritis.

2. Growing Awareness and Early Diagnosis
   Enhanced awareness campaigns and improved access to healthcare are contributing to the early diagnosis of psoriatic arthritis. Early detection allows for timely intervention, which increases demand for effective treatment options and supports market growth.

Market Scope

Psoriatic Arthritis Treatment Market Companies

• AbbVie Inc.
• Janssen Global Services, LLC (Johnson & Johnson)
• Novartis AG
• Amgen Inc.
• Biogen Inc.
• Pfizer Inc.
• Eli Lilly and Company
• UCB S.A.
• Bristol-Myers Squibb Company
• Merck & Co. Inc.

Segment Covered in the Report

By Drug Class

• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Non-biologics Disease-modifying Anti-rheumatic Drugs (DMARDs)
• Biologics Disease-modifying Anti-rheumatic Drugs
• Others

By Product Type

• Prescriptions
• OTC

By Route of Administration

• Topical
• Oral
• Injectable

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa